Health And Pharma

FDA Approves Niraparib Plus Abiraterone for BRCA2+ Prostate Cancer as the First Precision Therapy

FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive ...
Health And Pharma

Preoperative Radiation May Improve Antitumor Immune Response in HR+ HER2- Breast Cancer

Preoperative radiation improved T-cell infiltration in patients with HR+ HER2- breast cancer when administered in combination ...
Health And Pharma

Oral SERD Giredestrant Cuts Risk of Invasive Recurrence by 30% in Early ER+ Breast Cancer

Presented at 2025 SABCS, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease ...
Health And Pharma

Teclistamab plus Daratumumab Achieves an 83% Risk Reduction and Redefines Second Line Myeloma Care

The Phase 3 MajesTEC 3 trial showed that teclistamab plus daratumumab reduced the risk of progression or death by 83% and ...
Health And Pharma

GSK’s ADC Risvutatug Rezetecan Earns FDA Orphan Drug Status for Small Cell Lung Cancer

GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell ...
Health And Pharma

HER2CLIMB-05: Tucatinib Combination Cuts Progression Risk by 36% in HER2+ Metastatic Breast Cancer

The results from HER2CLIMB-05 study, presented at the 2025 SABCS annual meeting, demonstrated that tucatinib (TUKYSA) added ...
Health And Pharma

Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer

One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali ...
healthandpharma

Colibactin’s Molecular Blueprint Exposes How a Gut Microbial Toxin Triggers Colorectal Cancer

Harvard scientists have defined the exact DNA cross-link created by colibactin, a gut microbial toxin associated with colorectal cancer. By revealing how a central α-ketoiminium group targets AT-rich ...